ADIPOQ and metabolic disease: Given the modulatory role of adiponectin in adipogenesis and osteogenesis of MSC, deficits in adiponectin signaling, as observed in obesity and related metabolic disorders, may contribute to aberrant adipocyte proliferation and decrease the efficacy of MSC therapy for bone loss.